BioSpace News Archive

Ambry Genetics, a leader in clinical diagnostic testing and a subsidiary of REALM IDx, Inc., announced today the findings of a study that showed paired RNA and DNA genetic testing, conducted at the same time, detected elusive pathogenic variants in 1 of every 950 patients that were missed by DNA testing alone.

Recbio, an innovative vaccine company, released its interim result for the fiscal year 2022 in the evening of August 25.

Teva Pharmaceutical Industries Ltd. announces that the European Commission has granted a Marketing Authorization for Ranivisio, a biosimilar of the ophthalmology treatment Lucentis across all five indications in adults for which Lucentis is authorized.

Amgen presented new compelling data from the Phase 3 FOURIER open label extension studies of Repatha® in adults with atherosclerotic cardiovascular disease during the Aug. 29 late-breaking Hot Line Session of the European Society of Cardiology Annual Meeting being held in Barcelona, Spain, and online.

Össur has acquired Naked Prosthetics, a leading provider of durable, custom and functional finger prostheses for finger and partial hand amputees, with effect from 26 August 2022.

Alvotech, a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced that the Company has released data on environmental, social and governance indicators for 2020 and 2021, to provide further transparency to stakeholders.

ONK Therapeutics announced the first in-vivo data for ONKT102, a fully human, optimized affinity CD38 CAR-NK cell therapy.

Evolus, Inc. announced that members of its management team will be participating in the H.C. Wainwright 24th Annual Global Investment Conference.

At the International Mass Spectrometry Conference, Bruker Corporation announced the launch of the new nanoElute® 2 nano-LC, of MetaboScape® and TASQ® 2023 software supporting fluxomics, and of latest advances in PaSER™’s intelligent acquisition to enhance research in protein-protein interactions and metaproteomics applications.

MetasTx LLC announced that Jonathan Chernoff, MD, PhD, Director of Fox Chase Cancer Center and world-renowned expert in translational research, precision medicine, signaling reprograming, and targeted therapies, has joined MetasTx scientific advisory board.